We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Effect of Reduction of Inflammatory Status on Glucose Metabolism in Overweight Men

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: September 22, 2005
Last Update Posted: October 11, 2006
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:

Overweight increases the risk to develop chronic diseases including type-2 diabetes and cardiovascular disease. The low-grade inflammatory status often seen in overweight subjects is thought to play an important role in disease development.

The purpose of this study is to determine the role of inflammation on glucose metabolism and insulin resistance. In this study the effect of the anti-inflammatory treatment diclofenac on markers of inflammation and on parameters of glucose metabolism will be studied.

Condition Intervention
Overweight Obesity Inflammation Drug: Diclofenac

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Official Title: Relation Between Reduction of the Inflammatory Status and Glucose Metabolism in Healthy Overweight Men

Resource links provided by NLM:

Further study details as provided by TNO:

Estimated Enrollment: 20
Study Start Date: June 2005
Estimated Study Completion Date: July 2005

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Body Mass Index (BMI): 25.1 – 32.0 kg/m2
  • Normal Dutch eating habits

Exclusion Criteria:

  • diabetes, cardiovascular disease or hypertension
  • Not suitable to receive diclofenac treatment
  • Smoking
  • Extreme physical activity (more than 6 hours/week)
  • Reported slimming or medically prescribed diet
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00221052

TNO Quality of Life
Zeist, Netherlands, 3700 AJ
Sponsors and Collaborators
Principal Investigator: Trinette van Vliet, PhD TNO Quality of Life, Location Zeist
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00221052     History of Changes
Other Study ID Numbers: TNO-P6374
First Submitted: September 13, 2005
First Posted: September 22, 2005
Last Update Posted: October 11, 2006
Last Verified: October 2006

Additional relevant MeSH terms:
Pathologic Processes
Body Weight
Signs and Symptoms
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action